Blueprint Medicines Corporation (NASDAQ: BPMC) stock closed at 109.19 per share at the end of the most recent trading day (a 1.47% change compared to the prior day closing price) with a volume of 316.32K shares and market capitalization of 6.39B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 429 people. Blueprint Medicines Corporation CEO is Jeffrey W. Albers.

The one-year performance of Blueprint Medicines Corporation stock is 21.47%, while year-to-date (YTD) performance is -2.64%. BPMC stock has a five-year performance of 281.78%. Its 52-week range is between 79.07 and 125.61, which gives BPMC stock a 52-week price range ratio of 64.53%

Blueprint Medicines Corporation currently has a PE ratio of 17.80, a price-to-book (PB) ratio of 4.67, a price-to-sale (PS) ratio of 7.44, a price to cashflow ratio of 15.20, a PEG ratio of 2.32, a ROA of 27.98%, a ROC of 32.57% and a ROE of 35.03%. The company’s profit margin is 41.31%, its EBITDA margin is 41.70%, and its revenue ttm is $828.09 Million , which makes it $14.14 revenue per share.

Of the last four earnings reports from Blueprint Medicines Corporation, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.65 for the next earnings report. Blueprint Medicines Corporation’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for Blueprint Medicines Corporation is Strong Buy (1.32), with a target price of $111, which is +1.93% compared to the current price. The earnings rating for Blueprint Medicines Corporation stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Blueprint Medicines Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Blueprint Medicines Corporation has a Buy technical analysis rating based on Technical Indicators (ADX : 8.04, ATR14 : 3.07, CCI20 : 163.72, Chaikin Money Flow : 0.22, MACD : 3.95, Money Flow Index : 86.49, ROC : 11.63, RSI : 74.75, STOCH (14,3) : 96.31, STOCH RSI : 1.00, UO : 71.12, Williams %R : -3.69), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Blueprint Medicines Corporation in the last 12-months were: Anthony L. Boral (Option Excercise at a value of $266 767), Anthony L. Boral (Sold 10 000 shares of value $1 185 200 ), Ariel Hurley (Option Excercise at a value of $49 398), Ariel Hurley (Sold 13 564 shares of value $1 312 313 ), Becker Hewes (Option Excercise at a value of $579 600), Becker Hewes (Sold 13 125 shares of value $1 312 166 ), Charles A. Rowland (Option Excercise at a value of $307 653), Charles A. Rowland (Sold 20 909 shares of value $2 274 309 ), Christina Rossi (Sold 1 704 shares of value $152 313 ), Christopher K. Murray (Sold 1 210 shares of value $104 984 ), Debra Durso-Bumpus (Option Excercise at a value of $68 495), Debra Durso-Bumpus (Sold 3 593 shares of value $317 925 ), George D. Demetri (Sold 758 shares of value $85 010 ), Jeffrey W. Albers (Option Excercise at a value of $935 320), Jeffrey W. Albers (Sold 98 886 shares of value $9 386 857 ), Kathryn Haviland (Option Excercise at a value of $603 585), Kathryn Haviland (Sold 18 695 shares of value $1 856 005 ), Marion Dorsch (Option Excercise at a value of $793 338), Marion Dorsch (Sold 21 378 shares of value $2 170 000 ), Mark A. Goldberg (Option Excercise at a value of $827 229), Mark A. Goldberg (Sold 32 727 shares of value $3 681 795 ), Mark Alan Goldberg (Option Excercise at a value of $827 229), Mark Alan Goldberg (Sold 32 727 shares of value $3 681 795 ), Michael Landsittel (Sold 1 507 shares of value $130 749 ), Nicholas Lydon (Sold 9 815 shares of value $913 595 ), Tracey McCain (Sold 1 893 shares of value $164 242 )